新闻
ABBV
--
0.00%
--
20 只安全股息股票,让你辞掉朝九晚五的工作
In this article, we will be taking a look at 20 Safe Dividend Stocks to Quit Your 9 to 5 Job. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Safe Dividend Stocks to Quit Your 9 to 5 Job. Whether you are a veteran divi...
Insider Monkey · 10小时前
这是十年来最激动人心的医学突破吗
Financial News Media · 14小时前
眼科设备市场预期增长及其因素、CAGR、行业规模、业务前景和到2029年的预测
Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the global ophthalmology equipment market in terms of market segmentation by function of product, end-user, and by region.
AmericaNewsHour · 21小时前
退休计划集团购买 Vanguard Total World Bond ETF、摩根大通美国...
GuruFocus News · 1天前
更新 2-Oyster Point 的药物成为 FDA 批准的第一种治疗干眼症的鼻腔喷雾剂
reuters.com · 1天前
Polaris Wealth Advisory Group, LLC 购买 iShares iBoxx 美元高收益公司债券 ETF、Sysco ...
GuruFocus News · 1天前
BRIEF-Abbvie Receives CHMP Positive Opinion For Risankizumab For The Treatment Of Psoriatic Arthritis
reuters.com · 4天前
艾伯维 (AbbVie) 报告 CHMP 对 Risankizumab 在欧盟治疗成人活动性银屑病关节炎的积极意见
- CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2[1],[2] - If approved, this will mark the second indication for risankizumab in the EU[3] - Psoriatic arthritis is a systemic
CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2[1],[2] - If approved, this will mark the second indication for risankizumab in the EU[3] - Psoriatic arthritis is a systemic · 4天前
艾伯维 (AbbVie) 就 Risankizumab (SKYRIZI®) 在欧盟 (EU) 治疗成人活动性银屑病关节炎获得 CHMP 正面意见
AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI®, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereaft...
PR Newswire · 4天前
MADDEN SECURITIES Corp 收购 Penn National Gaming Inc、NVIDIA Corp、Coinbase Global Inc,出售...
GuruFocus News · 5天前
Winthrop 咨询集团有限责任公司购买 Dimensional US ...
GuruFocus News · 5天前
行业顾问表示,葛兰素史克应该考虑收购一家头痛公司
GuruFocus News · 5天前
这家公司彻底改变了对医院、大型制药公司和健康保险公司来说重要的事情
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs.
Benzinga · 5天前
资产管理公司收购 Alphabet Inc、Big 5 Sporting Goods Corp、通用汽车公司,出售...
GuruFocus News · 6天前
抗逆转录病毒蛋白酶抑制剂市场顶级公司、业务增长、规模和 2028 年预测
Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2028" which delivers detailed overview of the global antiretroviral protease inhibitors market in terms of market segmentation by mechanism of action, disease indicat...
AmericaNewsHour · 6天前
艾伯维 (ABBV) 跌幅超过大盘:你应该知道的
In the latest trading session, AbbVie (ABBV) closed at $110.34, marking a -0.76% move from the previous day.
Zacks · 10/11 21:45
Psyched:西雅图将迷幻药合法化,Psilocybin 增加了音乐的情绪,Novamind 的姑息治疗计划
The Week In Psychedelics Seattle Decriminalizes Psychedelics Along With California City
Benzinga · 10/11 18:21
这就是为什么艾伯维 (ABBV) 是一个伟大的股息股票
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Zacks · 10/11 15:45
Cannabis Movers & Shakers:Clairvoyant Therapeutics、Eaze、Leafly、Chalice Brands
As Benzinga Cannabis Capital Conference returns in a live format this coming week (Oct. 14-15)  in New York City, gathering top CEOs, investors, and leaders in the cannabis industry, let’s scroll through the latest leadership changes within the space.
Benzinga · 10/11 15:07
ChemoCentryx 任命风湿病学家 Rita I. Jain 为首席医疗官
Ahead of the launch of its first product, ChemoCentryx (NASDAQ:CCXI) has bolstered its executive team with the appointment of Rita I. Jain as the company’s new chief medical officer. Dr.
Seekingalpha · 10/11 12:43
微牛提供丰富的实时ABBV股票新闻,让你可以通过多个平台了解ABBV股票行情最新动态,这些免费的艾伯维新闻可以帮助你做出明智投资。
ABBV 简况
AbbVie Inc (AbbVie) 是一家以研究为基础的生物制药公司。该公司从事药物和疗法的研发、制造、商业化和销售。AbbVie提供各种治疗类别的产品,包括免疫学产品,其中包括Humira、Skyrizi和Rinvoq;肿瘤产品包括Imbruvica和Venclexta;美学产品包括Botox Cosmetic、Juvederm Collection等美学产品;神经科学产品,例如Botox Therapeutic、Vraylar、Duopa和Duodopa以及Ubrelvy;眼部护理产品包括Lumigan、Alphagan和Restasis;女性保健品包括Lo Loestrin、Orilissa等女性保健品;其他主要产品,包括Mavyret、Creon、Lupron、Linzess和Synthroid。该公司的产品通过AbbVie拥有的配送中心和公共仓库直接销往全球的批发商、分销商、政府机构、医疗保健机构和独立零售商。